-
1
-
-
0037216353
-
Review of 1027 patients with newly diagnosed multiple myeloma
-
Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.
-
(2003)
Mayo Clin Proc.
, vol.78
, pp. 21-23
-
-
Kyle, R.A.1
Gertz, M.A.2
Witzig, T.E.3
-
3
-
-
0043245842
-
Soluble receptor activator of nuclear factor kappaB ligand- osteoprotegerin ratio predicts survival in multiple myeloma: Proposal for a novel prognostic index
-
DOI 10.1182/blood-2003-02-0380
-
Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003;102:1064-9. (Pubitemid 36917805)
-
(2003)
Blood
, vol.102
, Issue.3
, pp. 1064-1069
-
-
Terpos, E.1
Szydlo, R.2
Apperley, J.F.3
Hatjiharissi, E.4
Politou, M.5
Meletis, J.6
Viniou, N.7
Yataganas, X.8
Goldman, J.M.9
Rahemtulla, A.10
-
4
-
-
0042822157
-
Activin a stimulates ikappab-Alpha/nfkappab and rank expression for osteoclast differentiation, but not akt survival pathway in osteoclast precursors
-
Sugatani T, Alvarez UM, Hruska KA. Activin A stimulates IkappaB-Alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem. 2003;90:59-67.
-
(2003)
J Cell Biochem.
, vol.90
, pp. 59-57
-
-
Sugatani, T.1
Alvarez, U.M.2
Hruska, K.A.3
-
6
-
-
84863959463
-
Sclerostin: A possible target for the management of cancer-induced bone disease
-
Gkotzamanidou M, Dimopoulos MA, Kastritis E, et al. Sclerostin: a possible target for the management of cancer-induced bone disease. Expert Opin Ther Targets. 2012;16:761-9.
-
(2012)
Expert Opin Ther Targets.
, vol.16
, pp. 761-769
-
-
Gkotzamanidou, M.1
Dimopoulos, M.A.2
Kastritis, E.3
-
7
-
-
0032956189
-
Economic impact of using clodronate in the management of patients with multiple myeloma
-
Bruce NJ, McCloskey EV, Kanis JA, et al. Economic impact of using clodronate in the management of patients with multiple myeloma. Br J Haematol. 1999;104:358-64.
-
(1999)
Br J Haematol.
, vol.104
, pp. 358-354
-
-
Bruce, N.J.1
McCloskey, E.V.2
Kanis, J.A.3
-
8
-
-
34447266200
-
An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
-
DOI 10.1016/j.ejca.2007.04.022, PII S0959804907003516
-
Cocks K, Cohen D, Wisløff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43:1670-8. (Pubitemid 47042371)
-
(2007)
European Journal of Cancer
, vol.43
, Issue.11
, pp. 1670-1678
-
-
Cocks, K.1
Cohen, D.2
Wisloff, F.3
Sezer, O.4
Lee, S.5
Hippe, E.6
Gimsing, P.7
Turesson, I.8
Hajek, R.9
Smith, A.10
Graham, L.11
Phillips, A.12
Stead, M.13
Velikova, G.14
Brown, J.15
-
9
-
-
35048875471
-
Pathologic fractures correlate with reduced survival in patients with malignant bone disease
-
DOI 10.1002/cncr.22991
-
Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860-7. (Pubitemid 47557312)
-
(2007)
Cancer
, vol.110
, Issue.8
, pp. 1860-1867
-
-
Saad, F.1
Lipton, A.2
Cook, R.3
Chen, Y.-M.4
Smith, M.5
Coleman, R.6
-
10
-
-
5444262558
-
Bisphosphonates: Clinical experience
-
Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004;9:14-27.
-
(2004)
Oncologist.
, vol.9
, pp. 14-17
-
-
Coleman, R.E.1
-
11
-
-
0025916366
-
Effect of daily etidronate on the osteolysis of multiple myeloma
-
Belch AR, Bergsagel DE,Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol. 1991;9:1397-402.
-
(1991)
J Clin Oncol.
, vol.9
, pp. 1397-1390
-
-
Belch, A.R.1
Bergsagel, D.E.2
Wilson, K.3
-
12
-
-
0027331171
-
Treatment of multiple myeloma with etidronate: Results of a multicentre double-blind study
-
Daragon A, Humez C, Michot C, et al. Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Eur J Med. 1993;2:449-52.
-
(1993)
Eur J Med.
, vol.2
, pp. 449-442
-
-
Daragon, A.1
Humez, C.2
Michot, C.3
-
13
-
-
0036570071
-
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma
-
DOI 10.1200/JCO.2002.02.032
-
Menssen HD, Sakalova A, Fontana A, et al. Effects of long-Term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol. 2002;20:2353-9. (Pubitemid 34441663)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.9
, pp. 2353-2359
-
-
Menssen, H.D.1
Sakalova, A.2
Fontana, A.3
Herrmann, Z.4
Boewer, C.5
Facon, T.6
Lichinitser, M.R.7
Singer, C.R.J.8
Euller-Ziegler, L.9
Wetterwald, M.10
Fiere, D.11
Hrubisko, M.12
Thiel, E.13
Delmas, P.D.14
-
14
-
-
0026646339
-
Randomised, placebocontrolled multicentre trial of clodronate in multiple myeloma
-
Lahtinen R, Laakso M, Palva I, et al. Randomised, placebocontrolled multicentre trial of clodronate in multiple myeloma. Lancet. 1992;40:1049-52.
-
(1992)
Lancet.
, vol.40
, pp. 1049-1042
-
-
Lahtinen, R.1
Laakso, M.2
Palva, I.3
-
15
-
-
0028106385
-
Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in muliple myeloma
-
Laakso M, Lahtinen R, Virkkunen P, et al. Subgroup and costbenefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Br J Haematol. 1994;87:725-9. (Pubitemid 24264643)
-
(1994)
British Journal of Haematology
, vol.87
, Issue.4
, pp. 725-729
-
-
Laakso, M.1
Lahtinen, R.2
Virkkunen, P.3
Elomaa, I.4
-
16
-
-
0031911183
-
A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Mrc working party on leukaemia in adults
-
McCloskey EV, MacLennan IC, Drayson MT, et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1998;100:317-25.
-
(1998)
Br J Haematol.
, vol.100
, pp. 317-315
-
-
McCloskey, E.V.1
MacLennan, I.C.2
Drayson, M.T.3
-
17
-
-
0034937438
-
Long-Term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma
-
McCloskey EV, Dunn JA, Kanis JA, et al. Long-Term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol. 2001;113:1035-43.
-
(2001)
Br J Haematol.
, vol.113
, pp. 1035-1033
-
-
McCloskey, E.V.1
Dunn, J.A.2
Kanis, J.A.3
-
18
-
-
9044219839
-
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma aredia study group
-
Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334:488-93.
-
(1996)
N Engl J Med.
, vol.334
, pp. 488-483
-
-
Berenson, J.R.1
Lichtenstein, A.2
Porter, L.3
-
19
-
-
6844252283
-
Long-Term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma aredia study group
-
Berenson JR, Lichtenstein A, Porter L, et al. Long-Term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16:593-602.
-
(1998)
J Clin Oncol.
, vol.16
, pp. 593-590
-
-
Berenson, J.R.1
Lichtenstein, A.2
Porter, L.3
-
20
-
-
0031810467
-
Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial
-
DOI 10.1046/j.1365-2141.1998.00695.x
-
Brincker H, Westin J, Abildgaard N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a doubleblind placebo-controlled trial. Danish-Swedish co-operative study group Br J Haematol. 1998;101:280-6. (Pubitemid 28261115)
-
(1998)
British Journal of Haematology
, vol.101
, Issue.2
, pp. 280-286
-
-
Brincker, H.1
Westin, J.2
Abildgaard, N.3
Gimsing, P.4
Turesson, I.5
Hedenus, M.6
Ford, J.7
Kandra, A.8
-
21
-
-
77957332677
-
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (nordic myeloma study group): A double-blind, randomised controlled trial
-
The only randomized study which compared two different dosages of pamidronate in myeloma patients
-
Gimsing P, Carlson K, Turesson I, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol. 2010;11:973-82. The only randomized study which compared two different dosages of pamidronate in myeloma patients.
-
(2010)
Lancet Oncol.
, vol.11
, pp. 973-972
-
-
Gimsing, P.1
Carlson, K.2
Turesson, I.3
-
22
-
-
0035312469
-
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
-
Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91:1191-200.
-
(2001)
Cancer.
, vol.91
, pp. 1191-1190
-
-
Berenson, J.R.1
Rosen, L.S.2
Howell, A.3
-
23
-
-
0035463593
-
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase iii, double-blind, comparative trial
-
Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377-87.
-
(2001)
Cancer J.
, vol.7
, pp. 377-377
-
-
Rosen, L.S.1
Gordon, D.2
Kaminski, M.3
-
24
-
-
10744233021
-
Long-Term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial
-
Rosen LS, Gordon D, Kaminski M, et al. Long-Term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735-44.
-
(2003)
Cancer.
, vol.98
, pp. 1735-1734
-
-
Rosen, L.S.1
Gordon, D.2
Kaminski, M.3
-
25
-
-
78650174738
-
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (mrc myeloma ix): A randomised controlled trial
-
The biggest randomized study in the field of bisphosphonates for the treatment of myeloma-related bone disease which compared oral clodronate and zoledronic acid. The study confirmed the superiority of zoledronic acid over clodronate not only regarding skeletal-related events but also regarding survival
-
Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376:1989-99. The biggest randomized study in the field of bisphosphonates for the treatment of myeloma-related bone disease which compared oral clodronate and zoledronic acid. The study confirmed the superiority of zoledronic acid over clodronate not only regarding skeletal-related events but also regarding survival.
-
(2010)
Lancet.
, vol.376
, pp. 99
-
-
Morgan, G.J.1
Davies, F.E.2
Gregory, W.M.3
-
26
-
-
79960891058
-
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (mrc myeloma ix): Secondary outcomes from a randomised controlled trial
-
Morgan GJ, Child JA, Gregory WM, et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol. 2011;12:743-52.
-
(2011)
Lancet Oncol.
, vol.12
, pp. 743-742
-
-
Morgan, G.J.1
Child, J.A.2
Gregory, W.M.3
-
27
-
-
84862524640
-
Effects of induction and maintenance plus long-Term bisphosphonates on bone disease in patients with multiple myeloma: Mrc myeloma ix trial
-
The updated analysis of the reference 25 which showed that the beneficial effect of zoledronic acid over clodronate continues even after two years following initiation of bisphosphonate therapy
-
Morgan GJ, Davies FE, Gregory WM, et al. Effects of induction and maintenance plus long-Term bisphosphonates on bone disease in patients with multiple myeloma: MRC Myeloma IX trial. Blood. 2012;119:5374-83. The updated analysis of the reference 25 which showed that the beneficial effect of zoledronic acid over clodronate continues even after two years following initiation of bisphosphonate therapy.
-
(2012)
Blood.
, vol.119
, pp. 5374-5373
-
-
Morgan, G.J.1
Davies, F.E.2
Gregory, W.M.3
-
28
-
-
34347260332
-
American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
-
Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25:2464-72.
-
(2007)
J Clin Oncol.
, vol.25
, pp. 2464-2462
-
-
Kyle, R.A.1
Yee, G.C.2
Somerfield, M.R.3
-
29
-
-
69449108135
-
The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the european myeloma network
-
Recommendations of the European Myeloma Network for the tretament of myeloma-related bone disease
-
Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol. 2009;20:1303-17. Recommendations of the European Myeloma Network for the tretament of myeloma-related bone disease.
-
(2009)
Ann Oncol.
, vol.20
, pp. 1303-1307
-
-
Terpos, E.1
Sezer, O.2
Croucher, P.I.3
-
30
-
-
33644841755
-
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors
-
DOI 10.1200/JCO.2005.02.8670
-
Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580-7. (Pubitemid 46211499)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.34
, pp. 8580-8587
-
-
Bamias, A.1
Kastritis, E.2
Bamia, C.3
Moulopoulos, L.A.4
Melakopoulos, I.5
Bozas, G.6
Koutsoukou, V.7
Gika, D.8
Anagnostopoulos, A.9
Papadimitriou, C.10
Terpos, E.11
Dimopoulos, M.A.12
-
31
-
-
33745792743
-
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid
-
Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91:968-71.
-
(2006)
Haematologica.
, vol.91
, pp. 968-961
-
-
Dimopoulos, M.A.1
Kastritis, E.2
Anagnostopoulos, A.3
-
32
-
-
33747426633
-
Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients
-
DOI 10.1111/j.1365-2141.2006.06230.x
-
Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol. 2006;134:620-3. (Pubitemid 44253605)
-
(2006)
British Journal of Haematology
, vol.134
, Issue.6
, pp. 620-623
-
-
Zervas, K.1
Verrou, E.2
Teleioudis, Z.3
Vahtsevanos, K.4
Banti, A.5
Mihou, D.6
Krikelis, D.7
Terpos, E.8
-
33
-
-
58049204529
-
Natural history of osteonecrosis of the jaw in patients with multiple myeloma
-
Badros A, Terpos E, Katodritou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol. 2008;26:5904-9.
-
(2008)
J Clin Oncol.
, vol.26
, pp. 5904-5909
-
-
Badros, A.1
Terpos, E.2
Katodritou, E.3
-
34
-
-
58949104001
-
Reduction of osteonecrosis of the jaw (onj) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
-
An important study which showed for the first time that the implementation of dental preventive measures reduces the incidence of ONJ in myeloma patients who receive bisphosphonates
-
Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20:117-20. An important study which showed for the first time that the implementation of dental preventive measures reduces the incidence of ONJ in myeloma patients who receive bisphosphonates.
-
(2009)
Ann Oncol.
, vol.20
, pp. 117-110
-
-
Dimopoulos, M.A.1
Kastritis, E.2
Bamia, C.3
-
35
-
-
57049173860
-
Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates
-
Montefusco V, Gay F, Spina F, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma. 2008;49:2156-62.
-
(2008)
Leuk Lymphoma.
, vol.49
, pp. 2156-2152
-
-
Montefusco, V.1
Gay, F.2
Spina, F.3
-
36
-
-
29144436466
-
Managing the care of patients with bisphosphonate-Associated osteonecrosis: An american academy of oral medicine position paper
-
Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-Associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005;136:1658-68.
-
(2005)
J Am Dent Assoc.
, vol.136
, pp. 1658-1658
-
-
Migliorati, C.A.1
Casiglia, J.2
Epstein, J.3
-
38
-
-
21044454594
-
Esmo minimum clinical recommendations for diagnosis, treatment and follow-up of multiple myeloma
-
ESMO Guidelines Task Force
-
Harrouseau JL, Greil R, Kloke O. ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma. Ann Oncol. 2005;16:45-7.
-
(2005)
Ann Oncol.
, vol.16
, pp. 45-47
-
-
Harrouseau, J.L.1
Greil, R.2
Kloke, O.3
-
39
-
-
33746855407
-
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma
-
Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81:1047-53.
-
(2006)
Mayo Clin Proc.
, vol.81
, pp. 1047-1043
-
-
Lacy, M.Q.1
Dispenzieri, A.2
Gertz, M.A.3
-
40
-
-
34047200362
-
Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement [1]
-
Durie BG. Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc. 2007;82:516-57. (Pubitemid 46543476)
-
(2007)
Mayo Clinic Proceedings
, vol.82
, Issue.4
, pp. 516-517
-
-
Durie, B.G.M.1
-
41
-
-
54049124120
-
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
-
Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008;113:1588-95.
-
(2008)
Cancer.
, vol.113
, pp. 1588-1585
-
-
Musto, P.1
Petrucci, M.T.2
Bringhen, S.3
-
42
-
-
34250313823
-
A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma
-
DOI 10.1038/sj.leu.2404682, PII 2404682
-
Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia. 2007;21:1545-8. (Pubitemid 46965296)
-
(2007)
Leukemia
, vol.21
, Issue.7
, pp. 1545-1548
-
-
Corso, A.1
Varettoni, M.2
Zappasodi, P.3
Klersy, C.4
Mangiacavalli, S.5
Pica, G.6
Lazzarino, M.7
-
43
-
-
77957991625
-
The use of biochemical markers of bone remodeling in multiple myeloma: A report of the internationalmyelomaworking group
-
Terpos E, Dimopoulos MA, Sezer O, et al. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the InternationalMyelomaWorking Group. Leukemia. 2010;24:1700-12.
-
(2010)
Leukemia.
, vol.24
, pp. 1700-1702
-
-
Terpos, E.1
Dimopoulos, M.A.2
Sezer, O.3
-
44
-
-
0036181668
-
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity
-
Yaccoby S, Pearse RN, Johnson CL, et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 2002;116:278-90.
-
(2002)
Br J Haematol.
, vol.116
, pp. 278-270
-
-
Yaccoby, S.1
Pearse, R.N.2
Johnson, C.L.3
-
45
-
-
0037439916
-
Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma
-
Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res. 2003;63:287-9. (Pubitemid 36152481)
-
(2003)
Cancer Research
, vol.63
, Issue.2
, pp. 287-289
-
-
Vanderkerken, K.1
De Leenheer, E.2
Shipman, C.3
Asosingh, K.4
Willems, A.5
Van Camp, B.6
Croucher, P.7
-
46
-
-
58649113384
-
Denosumab, a fully human monoclonal antibody to rankl, inhibits bone resorption and increases bmd in knock-in mice that express chimeric (murine/human) rankl
-
Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009;24:182-95.
-
(2009)
J Bone Miner Res.
, vol.24
, pp. 182-185
-
-
Kostenuik, P.J.1
Nguyen, H.Q.2
McCabe, J.3
-
47
-
-
79952761418
-
Randomized, doubleblind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
-
Henry DH, Costa L, Goldwasser F, et al. Randomized, doubleblind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125-32.
-
(2011)
J Clin Oncol.
, vol.29
, pp. 1125-1122
-
-
Henry, D.H.1
Costa, L.2
Goldwasser, F.3
-
48
-
-
20344396891
-
The innate functions of dendritic cells in peripheral lymphoid tissues
-
Steinman RM, Bonifaz L, Fujii S, et al. The innate functions of dendritic cells in peripheral lymphoid tissues. Adv Exp Med Biol. 2005;560:83-97.
-
(2005)
Adv Exp Med Biol.
, vol.560
, pp. 83-87
-
-
Steinman, R.M.1
Bonifaz, L.2
Fujii, S.3
-
49
-
-
77950438331
-
Activin a promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
-
The first paper addressing the role of activin-A in myeloma-related bone disease
-
Vallet S, Mukherjee S, Vaghela N, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. ProcNatl Acad SciUS A. 2010;107:5124-9. The first paper addressing the role of activin-A in myeloma-related bone disease.
-
(2010)
ProcNatl Acad SciUS A.
, vol.107
, pp. 5124-5129
-
-
Vallet, S.1
Mukherjee, S.2
Vaghela, N.3
-
50
-
-
84867135322
-
Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy
-
Forthcoming
-
Terpos E, Kastritis E, Christoulas D, et al. Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol. Forthcoming 2012.
-
(2012)
Ann Oncol.
-
-
Terpos, E.1
Kastritis, E.2
Christoulas, D.3
-
51
-
-
44349141964
-
A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity
-
DOI 10.1073/pnas.0711263105
-
Pearsall SR, Canalis E, Cornwall-Brady M, et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci U S A. 2008;105:7082-7. (Pubitemid 351754533)
-
(2008)
Proceedings of the National Academy of Sciences of the United States of America
, vol.105
, Issue.19
, pp. 7082-7087
-
-
Pearsall, R.S.1
Canalis, E.2
Cornwall-Brady, M.3
Underwood, K.W.4
Haigis, B.5
Ucran, J.6
Kumar, R.7
Pobre, E.8
Grinberg, A.9
Werner, E.D.10
Glatt, V.11
Stadmeyer, L.12
Smith, D.13
Seehra, J.14
Bouxsein, M.L.15
-
52
-
-
0346363760
-
The role of the wnt-signaling antagonist dkk1 in the development of osteolytic lesions in multiple myeloma
-
Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483-94.
-
(2003)
N Engl J Med.
, vol.349
, pp. 2483-2484
-
-
Tian, E.1
Zhan, F.2
Walker, R.3
-
53
-
-
33747468221
-
Serum concentrations of dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation
-
Politou MC, Heath DJ, Rahemtulla A, et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer. 2006;119:1728-31.
-
(2006)
Int J Cancer.
, vol.119
, pp. 1728-1721
-
-
Politou, M.C.1
Heath, D.J.2
Rahemtulla, A.3
-
54
-
-
84872193696
-
Dickkopf-1 is elevated in newly-diagnosed, symptomatic patients and in relapsed patients with multiple myeloma. Correlations with advanced disease features: A single-center experience in 284 patients [abstract]
-
Terpos E, Christoulas D, Papatheodorou A, et al. Dickkopf-1 is elevated in newly-diagnosed, symptomatic patients and in relapsed patients with multiple myeloma. correlations with advanced disease features: a single-center experience in 284 patients [abstract]. Haematologica. 2010;95 Suppl 2:384.
-
(2010)
Haematologica.
, vol.95
, Issue.SUPPL. 2
, pp. 384
-
-
Terpos, E.1
Christoulas, D.2
Papatheodorou, A.3
-
55
-
-
67650431302
-
Anti-dkk1 mab (bhq880) as a potential therapeutic agent for multiple myeloma
-
Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009;114:371-9.
-
(2009)
Blood.
, vol.114
, pp. 371-379
-
-
Fulciniti, M.1
Tassone, P.2
Hideshima, T.3
-
56
-
-
61849137831
-
Inhibiting dickkopf-1 (dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma
-
Heath DJ, Chantry AD, Buckle CH, et al. Inhibiting dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res. 2009;24:425-36.
-
(2009)
J Bone Miner Res.
, vol.24
, pp. 425-426
-
-
Heath, D.J.1
Chantry, A.D.2
Buckle, C.H.3
-
57
-
-
22244474640
-
Genomic deletion of a longrange bone enhancer misregulates sclerostin in Van Buchem disease
-
Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a longrange bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005;15:928-35.
-
(2005)
Genome Res.
, vol.15
, pp. 928-925
-
-
Loots, G.G.1
Kneissel, M.2
Keller, H.3
-
58
-
-
84857440881
-
Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women -The six-month effect of risedronate and teriparatide
-
Polyzos SA, Anastasilakis AD, Bratengeier C, et al. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women -The six-month effect of risedronate and teriparatide. Osteoporos Int. 2012;23:1171-6.
-
(2012)
Osteoporos Int.
, vol.23
, pp. 1171-1176
-
-
Polyzos, S.A.1
Anastasilakis, A.D.2
Bratengeier, C.3
-
59
-
-
84869509300
-
High circulating sclerostin is present in patients with thalassemia-Associated osteoporosis and correlates with bone mineral density
-
Forthcoming
-
Voskaridou E, Christoulas D, Plata E, et al. High circulating sclerostin is present in patients with thalassemia-Associated osteoporosis and correlates with bone mineral density. Horm Metab Res. Forthcoming 2012.
-
(2012)
Horm Metab Res.
-
-
Voskaridou, E.1
Christoulas, D.2
Plata, E.3
-
60
-
-
84864144433
-
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma; reduction postbortezomib monotherapy
-
The first paper addressing the role of sclerostin in myeloma-related bone disease
-
Terpos E, Christoulas D, Katodritou E, et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma; reduction postbortezomib monotherapy. Int J Cancer. 2012;131:1466-71. The first paper addressing the role of sclerostin in myeloma-related bone disease.
-
(2012)
Int J Cancer.
, vol.131
, pp. 1466-1461
-
-
Terpos, E.1
Christoulas, D.2
Katodritou, E.3
-
61
-
-
84859631972
-
Sclerostin: A novel target for intervention in the treatment of osteoporosis
-
Lewiecki EM. Sclerostin: a novel target for intervention in the treatment of osteoporosis. Discov Med. 2011;12:263-73.
-
(2011)
Discov Med.
, vol.12
, pp. 263-263
-
-
Lewiecki, E.M.1
-
62
-
-
33750566914
-
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappab ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
-
Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol. 2006;135:688-92.
-
(2006)
Br J Haematol.
, vol.135
, pp. 688-682
-
-
Terpos, E.1
Heath, D.J.2
Rahemtulla, A.3
-
63
-
-
34347400592
-
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
-
DOI 10.1182/blood-2006-11-059188
-
Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 2007;110:334-8. (Pubitemid 47026851)
-
(2007)
Blood
, vol.110
, Issue.1
, pp. 334-338
-
-
Giuliani, N.1
Morandi, F.2
Tagliaferri, S.3
Lazzaretti, M.4
Bonomini, S.5
Crugnola, M.6
Mancini, C.7
Martella, E.8
Ferrari, L.9
Tabilio, A.10
Rizzoli, V.11
-
64
-
-
77954253348
-
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid
-
Terpos E, Christoulas D, Kokkoris P, et al. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol. 2010;21:1561-2.
-
(2010)
Ann Oncol.
, vol.21
, pp. 1561-1562
-
-
Terpos, E.1
Christoulas, D.2
Kokkoris, P.3
-
65
-
-
57849161431
-
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
-
Terpos E, Kastritis E, Roussou M, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia. 2008;22:2247-56.
-
(2008)
Leukemia.
, vol.22
, pp. 2247-2246
-
-
Terpos, E.1
Kastritis, E.2
Roussou, M.3
-
66
-
-
79954426340
-
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase iii vista trial in multiple myeloma
-
The first randomized study confirming the beneficial effect of bortezomib on bone metabolism of myeloma patients who receive front-line therapy
-
Delforge M, Terpos E, Richardson PG, et al. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol. 2011;86:372-84. The first randomized study confirming the beneficial effect of bortezomib on bone metabolism of myeloma patients who receive front-line therapy.
-
(2011)
Eur J Haematol.
, vol.86
, pp. 372-374
-
-
Delforge, M.1
Terpos, E.2
Richardson, P.G.3
-
67
-
-
79956042305
-
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients
-
Zangari M, Aujay M, Zhan F, et al. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011;86:484-7.
-
(2011)
Eur J Haematol.
, vol.86
, pp. 484-487
-
-
Zangari, M.1
Aujay, M.2
Zhan, F.3
-
68
-
-
84873566871
-
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-Anabolic activity in addition to anti-myeloma effects
-
doi:10.1038/leu.2012.183
-
Hurchla MA, Garcia-Gomez A, Hornick MC, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-Anabolic activity in addition to anti-myeloma effects. Leukemia. 2012. doi:10.1038/leu.2012.183.
-
(2012)
Leukemia.
-
-
Hurchla, M.A.1
Garcia-Gomez, A.2
Hornick, M.C.3
-
69
-
-
27644523704
-
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of srankl/osteoprotegerin ratio
-
Terpos E, Mihou D, Szydlo R, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia. 2005;19:1969-76.
-
(2005)
Leukemia.
, vol.19
, pp. 1969-1966
-
-
Terpos, E.1
Mihou, D.2
Szydlo, R.3
-
70
-
-
33645725851
-
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma
-
Tosi P, Zamagni E, Cellini C, et al. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol. 2006;76:399-404.
-
(2006)
Eur J Haematol.
, vol.76
, pp. 399-390
-
-
Tosi, P.1
Zamagni, E.2
Cellini, C.3
-
71
-
-
54049156803
-
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
-
Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia. 2008;22:1925-32.
-
(2008)
Leukemia.
, vol.22
, pp. 1925-1922
-
-
Breitkreutz, I.1
Raab, M.S.2
Vallet, S.3
-
72
-
-
84905057738
-
The combination of lenalidomide and dexamethasone (rd) reduces bone resorption in responding patients with relapsed/refractory multiple myeloma (mm) but has no effect on bone formation: Results of a retrospective analysisand a prospective studyon205patients,onbehalf of thegreek myeloma study group [abstract]
-
Terpos E, Christoulas D, Katodritou E, et al. The combination of lenalidomide and dexamethasone (RD) reduces bone resorption in responding patients with relapsed/refractory multiple myeloma (MM) but has no effect on bone formation: results of a retrospective analysisand a prospective studyon205patients,onbehalf of theGreek myeloma study group [abstract]. Haematologica. 2011;96 Suppl 1:65.
-
(2011)
Haematologica.
, vol.96
, Issue.SUPPL. 1
, pp. 65
-
-
Terpos, E.1
Christoulas, D.2
Katodritou, E.3
-
73
-
-
33645736007
-
Thalidomide derivative cc-4047 inhibits osteoclast formation by down-regulation of pu.1
-
Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006;107:3098-105.
-
(2006)
Blood.
, vol.107
, pp. 3098-3090
-
-
Anderson, G.1
Gries, M.2
Kurihara, N.3
-
74
-
-
79954427850
-
Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: Long-Term experience
-
Balducci M, Chiesa S, Manfrida S, et al. Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: long-Term experience. Strahlenther Onkol. 2011;187:114-9.
-
(2011)
Strahlenther Onkol.
, vol.187
, pp. 114-119
-
-
Balducci, M.1
Chiesa, S.2
Manfrida, S.3
-
75
-
-
34250001092
-
Outcome after radiotherapy alone for metastatic spinal cord compression in patients with oligometastases
-
DOI 10.1200/JCO.2006.08.7155
-
Rades D, Veninga T, Stalpers LJ, et al. Outcome after radiotherapy alone for metastatic spinal cord compression in patients with oligometastases. J Clin Oncol. 2007;25:50-6. (Pubitemid 350003050)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.1
, pp. 50-56
-
-
Rades, D.1
Veninga, T.2
Stalpers, L.J.A.3
Basic, H.4
Rudat, V.5
Karstens, J.H.6
Dunst, J.7
Schild, S.E.8
-
76
-
-
0022552036
-
Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases
-
Price P, Hoskin PJ, Easton D, et al. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol. 1986;6:247-55.
-
(1986)
Radiother Oncol.
, vol.6
, pp. 247-245
-
-
Price, P.1
Hoskin, P.J.2
Easton, D.3
-
77
-
-
79952040181
-
Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: A multicentre, randomised controlled trial
-
The first randomized study revealing the value of balloon kyphoplasty for the treatment of painful vertebral fractures
-
Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol. 2011;12:225-35. The first randomized study revealing the value of balloon kyphoplasty for the treatment of painful vertebral fractures.
-
(2011)
Lancet Oncol.
, vol.12
, pp. 225-225
-
-
Berenson, J.1
Pflugmacher, R.2
Jarzem, P.3
-
78
-
-
70349423596
-
Balloon kyphoplasty in malignant spinal fractures: A systematic review and metaanalysis
-
Bouza C, Lopez-Cuadrado T, Cediel P, et al. Balloon kyphoplasty in malignant spinal fractures: a systematic review and metaanalysis. BMC Palliat Care. 2009;8:12.
-
(2009)
BMC Palliat Care
, vol.8
, pp. 12
-
-
Bouza, C.1
Lopez-Cuadrado, T.2
Cediel, P.3
-
79
-
-
42449162207
-
Vertebroplasty in multiple myeloma: Outcomes in a large patient series
-
DOI 10.3174/ajnr.A0918
-
McDonald RJ, Trout AT, Gray LA, et al. Vertebroplasty in multiple myeloma: outcomes in a large patient series. AJNR Am J Neuroradiol. 2008;29:642-8. (Pubitemid 351571539)
-
(2008)
American Journal of Neuroradiology
, vol.29
, Issue.4
, pp. 642-648
-
-
McDonald, R.J.1
Trout, A.T.2
Gray, L.A.3
Dispenzieri, A.4
Thielen, K.R.5
Kallmes, D.F.6
-
80
-
-
84872187713
-
Management of cancerrelated vertebral compression fracture: Comparison of treatment options; a literature meta-Analysis [abstract]
-
abstract
-
Bhargava A, Trivedi D, Kalva L, et al. Management of cancerrelated vertebral compression fracture: comparison of treatment options; a literature meta-Analysis [abstract]. J Clin Oncol. 2009;27(Suppl:abstract):e20529.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.SUPPL.
-
-
Bhargava, A.1
Trivedi, D.2
Kalva, L.3
-
81
-
-
0034857406
-
Surgical treatment for pathologic fracture
-
Wedin R. Surgical treatment for pathologic fracture. Acta Orthop Scand Suupl. 2001;72(2p):1-29.
-
(2001)
Acta Orthop Scand Suupl.
, vol.72
, Issue.2 P
, pp. 1-9
-
-
Wedin, R.1
-
82
-
-
80555149382
-
Surgical therapy of skeletal complications in multiple myeloma
-
Utzschneider S, Schmidt H,Weber P, et al. Surgical therapy of skeletal complications in multiple myeloma. Int Orthop. 2011;35:1209-13.
-
(2011)
Int Orthop.
, vol.35
, pp. 1209-1203
-
-
Utzschneider, S.1
Schmidt, H.2
Weber, P.3
|